![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The consensus EPS estimate for the quarter has been revised 6% higher over the last 30 days to the current level.įulcrum Therapeutics, Inc.'s revenues are expected to be $2.19 million, down 55.8% from the year-ago quarter. This company is expected to post quarterly loss of $0.62 per share in its upcoming report, which represents a year-over-year change of -8.8%. (FULC), another stock in the same industry, has yet to report results for the quarter ended September 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.įulcrum Therapeutics, Inc. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 20% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Horizon Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Horizon Therapeutics shares have lost about 41.4% since the beginning of the year versus the S&P 500's decline of -19.1%. ![]() The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ![]() The company has topped consensus revenue estimates three times over the last four quarters. This compares to year-ago revenues of $1.04 billion. Horizon Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $925.36 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 4.10%. ![]() Over the last four quarters, the company has surpassed consensus EPS estimates three times. A quarter ago, it was expected that this drugmaker would post earnings of $1.35 per share when it actually produced earnings of $1.07, delivering a surprise of -20.74%. This quarterly report represents an earnings surprise of 25%. These figures are adjusted for non-recurring items. This compares to earnings of $1.75 per share a year ago. Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1 per share. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |